The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Dosing patterns for octreotide LAR in neuroendocrine tumor (NET) patients: NCCN NET outcomes database.
Jonathan R. Strosberg
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Sarah Bobiak
Employment or Leadership Position - Bristol-Myers Squibb (I)
Carrie C. Zornosa
No relevant relationships to disclose
Michael A. Choti
Research Funding - Ipsen
Emily K. Bergsland
Consultant or Advisory Role - Ipsen (U); Lexicon (U); Novartis (U)
Research Funding - Lexicon; Novartis
Al Bowen Benson
Consultant or Advisory Role - Bayer/Onyx; Biocompatibles; Daiichi Sankyo; Genentech; Genomic Health; Infinity; Lilly; Precision Therapeutics; Vista Med
Research Funding - Abbott Laboratories; Amgen; Astellas Pharma; Bayer/Onyx; Genentech/Roche; Gilead Sciences; MDS Nordion
Other Remuneration - Genentech/Roche
Mark Bloomston
No relevant relationships to disclose
Matthew Kulke
Consultant or Advisory Role - Ipsen; Lexicon; Novartis; Pfizer
Manisha H. Shah
Research Funding - Novartis
James C. Yao
Consultant or Advisory Role - Novartis